Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 10/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.80 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GALR3 | O60755 | 1/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.65 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.65 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toyocamycin SCHEMBL2786616 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL17395285 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL29363964 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL13064386 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL20438004 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL14642992 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL14642728 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL2786620 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL336095 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| SCHEMBL16978197 | 0.89 | ADK (1.00) | ADKDOT1LPAX8NPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20190038597-A1 | PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION | MCMASTER UNIVERSITY (CA) | 2019-02-07 | — | — | US | disclosed |
| WO-2015120314-A1 | POLYPEPTIDES HAVING NITRILE HYDRATASE ACTIVITY AND POLYNUCLEOTIDES ENCODING THE SAME | ARIZONA BOARD OF REGENTS FOR THE UNIVERSITY OF ARIZONA (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038597-A1 | PREVENTION OF VASCULAR AND CARDIAC FIBROSIS VIA IRE1ALPHA INHIBITION | XBP1, ERN1, ERN2 | ADK 1657/4885DOT1L 3893/4885PAX8 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.